Reactive metabolites in early drug development: Predictive in vitro tools

Current Medicinal Chemistry

Volumn 22, Issue 4, 2015, Pages 538-550

  Pelkonen, Olavi ^a,b   Pasanen, Markku ^c   Tolonen, Ari ^d   Koskinen, Mikko ^e   Hakkola, Jukka ^a,b   Abass, Khaled ^a,f   Laine, Jaana ^c   Häkkinen, Merja ^c   Juvonen, Risto ^c   Auriola, Seppo ^c   Storvik, Markus ^c   Huuskonen, Pasi ^c   Rousu, Timo ^d   Rahikkala, Maiju ^d  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Admescope Ltd   (Finland)

^e ORION CORPORATION   (Finland)

^f MENOUFIA UNIVERSITY   (Egypt)

Author keywords

CYP; Cytochrome P450; Drug metabolizing enzymes; Glutathione; Oligonucleotide trappers; Oligopeptide trappers; Potassium cyanide; Reactive metabolites; Semicarbazide; Trapping agents

Indexed keywords

CYTOCHROME P450; DEOXYRIBONUCLEOTIDE; DRUG METABOLITE; DRUG METABOLIZING ENZYME; OLIGOPEPTIDE; TRANSCRIPTION FACTOR NRF2; DRUG; OLIGONUCLEOTIDE;

ARTICLE; BIOLOGY; CELL LINE; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG TOXICITY; HUMAN; METABOLITE; NONHUMAN; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; DRUG SCREENING; IN VITRO STUDY; METABOLIC ACTIVATION; METABOLISM; PROCEDURES;

ACTIVATION, METABOLIC; ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; IN VITRO TECHNIQUES; OLIGONUCLEOTIDES; OLIGOPEPTIDES; PHARMACEUTICAL PREPARATIONS;

EID: 84931268498     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666141012175543     Document Type: Article

References (50)

1. Baillie, T.A. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol., 2006, 19, 889-893.
2. Park, B.K.; Kitteringham, N.R.; Maggs, J.L.; Pirmohamed, M.; Williams, D.P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 177-202.
3. Park, B.K.; Boobis, A.; Clarke, S.; Goldring, C.E.; Jones, D.; Kenna, J.G.; Lambert, C.; Laverty, H.G.; Naisbitt, D.J.; Nelson, S.; Nicoll-Griffith, D.A.; Obach, R.S.; Routledge, P.; Smith, D.A.; Tweedie, D.J.; Vermeulen, N.; Williams, D.P.; Wilson, I.D.; Baillie, T.A. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov., 2011, 10, 292-306.
4. McCann, J.; Choi, E.; Yamasaki, E.; Ames, B.N. Detection of carcinogens in the Salmonella/microsome test. Assay of 300 chemicals. Proc. Natl. Acad. Sci. U.S.A., 1975, 72, 5135-5139.
5. Gan, J.; Qian, R.; Bing, H.; Mingshe, Z.; Wen, C.S. In vitro screening of 50 highly prescribed drugs for thiol adduct formation- comparison of potential for drug induced toxicity and extent of adduct formation, Chem. Res. Toxicol., 2009, 22, 690-698.
6. Stepan, A.F.; Walker, D.P.; Bauman, J.; Price, D.A.; Baillie, T.A.; Kalgutkar, A.S.; Aleo, M.D. Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States, Chem. Res. Toxicol., 2011, 24, 1345-1410.
7. Fontana, E.; Dansette, P.M.; Poli, S.M. Cytochrome P450 enzymes mechanism based inhibitors: Common sub-structures and reactivity. Curr. Drug Metab., 2005, 6, 413-454.
8. Rousu, T.; Pelkonen, O.; Tolonen, A. Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. Rapid Commun Mass Spectrom., 2009; 23: 843-855.
9. Rousu, T.; Hokkanen, J.; Pelkonen, O.; Tolonen, A. Applicability of generic assays based on liquid chromatography-electrospray mass spectrometry to study in vitro metabolism of 55 structurally diverse compounds. Frontiers in Pharmacology-Drug Metabolism and Transport, 2010, doi: 10.3389/fphar.2010.00010
10. Laine, J.E.; Auriola, S.; Pasanen, M.; Juvonen, R.O. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica, 2009, 39: 11-21.
11. Laine, J.E.; Auriola, S.; Pasanen, M.; Juvonen, R.O. D isomer of gly-tyr-pro-cys-pro-his-pro peptide. A novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry. Toxicol. In vitro, 2011, 25, 411-425 .
12. Obach, R.S.; Walsky, R.L.; Venkatakrishnan K., Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions, Drug Metab. Dispos., 2007, 35, 245-255.
13. Pelkonen, O.; Turpeinen, M.; Hakkola, J.; Honkakoski, P.; Hukkanen, J.; Raunio, H. Inhibition and induction of human cytochrome P450 enzymes-current status. Arch. Toxicol., 2008, 82, 667-715.
14. Turpeinen, M.; Uusitalo, J.; Jalonen, J.; Pelkonen, O. Multiple P450 substrates in a single run: rapid, comprehensive and clinically relevant in vitro interaction and metabolism assay. Eur. J. Pharm. Sci., 2005, 24, 123-132.
15. Tolonen, A.; Turpeinen, M.; Pelkonen, O. Liquid chromatographymass spectrometry in in vitro drug metabolite screening. Drug Discov. Today, 2009, 14, 120-133.
16. Tolonen, A.; Petsalo, A.; Turpeinen, M.; Uusitalo, J.; Pelkonen, O. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with thirteen probe reactions and a single LC/MSMS run; analytical validation and testing with monoclonal anti-CYP antibodies. J. Mass Spectrom., 2007, 42, 960-966.
17. Pelkonen, O.; Turpeinen, M.; Hakkola, J.; Abass, K.; Pasanen, M.; Raunio, H.; Vähäkangas, K. Preservation, induction or incorporation of metabolism into the in vitro cellular system-Views to current opportunities and limitations. Toxicol. In vitro, 2013, 27, 1578-1583.
18. Abass, K.; Reponen, P.; Mattila, S.; Pelkonen, O. Metabolism of Carbosulfan. II. Human interindividual variability in its in vitro he patic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem-Biol. Interact., 2010, 185, 163-173.
19. Turpeinen, M.; Ghiciuc, C.; Opritoui, M.; Kankainen, L.; Pelkonen, O.; Pasanen, M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated enzymes: A comparative study in vitro. Xenobiotica, 2007, 37, 1367-1377.
20. Turpeinen, M.; Tolonen, A.; Uusitalo, J.; Chesne, C.; Guillouzo, A.; Pelkonen, O. Functional Expression of Cytochrome P450 Enzymes in Human Hepatoma HepaRG Cell Line. Toxicol. In vitro, 2009, 23, 748-753.
21. Pasanen, M. The expression and regulation of drug metabolism in human placenta. Adv. Drug. Deliv. Rev., 1999, 38, 81-97.
22. Storvik, M.; Huuskonen, P.; Kyllönen, T.; Lehtonen, S.; El-Nezami, H.; Auriola, S.; Pasanen, M. Aflatoxin B1-a potential endocrine disruptor-up-regulates CYP19A1 in JEG-3 cells. Toxicol. Lett., 2011, 202, 161-167.
23. Huuskonen, P.; Myllynen, P.; Storvik, M.; Pasanen, M. The effects of aflatoxin B1 on transporters and steroid metabolizing enzymes in JEG-3 cells. Toxicol. Lett., 2013, 218, 200-206.
24. Ma, S.; Subramanian, R. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom., 2006, 41(9), 1121-1139.
25. Baillie, T.A.; Davis, M.R. Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom., 1993, 22(6), 319-325.
26. Zhu, M.; Ma, L.; Zhang, H.; Humphreys, W.G. Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering. Anal. Chem., 2007, 79(21), 8333-8341.
27. Zhang, K.E.; Naue, J.A.; Arison, B.; Vyas, K.P. Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: evidence for furan bioactivation. Chem. Res. Toxicol., 1996, 9(2), 547-554.
28. Xu, S.; Zhu, B.; Teffera, Y.; Pan, D.E.; Caldwell, C.G.; Doss, G.; Stearns, R.A.; Evans, D.C.; Beconi, M.G. Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes. Drug Metab. Dispos., 2005, 33(1), 121-130.
29. Meneses-Lorente, G.; Sakatis, M.Z.; Schulz-Utermoehl, T.; De Nardi, C.; Watt, A.P. A quantitative high-throughput trapping assay as a measurement of potential for bioactivation. Anal Biochem., 2006, 351(2), 266-272.
30. Argoti, D.; Liang, L.; Conteh, A.; Chen, L.; Bershas, D.; Yu, C-P.; Vouros, P.; Yang, E. Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem. Res. Toxicol., 2005, 18, 1537-1544.
31. Rousu, T.; Tolonen, A. Characterization of cyanide-trapped methylated metabonates formed during reactive drug metabolite screening in vitro. Rapid Commun. Mass Spectrom., 2011, 25, 1382-1390.
32. Yan, Z.; Maher, N.; Torres, R.; Cladwell, G.W.; Huebert, N. Use of a trapping agent for simultaneous capturing and high throughput screening for both soft and hard electrophiles. Anal. Chem., 2007, 79, 4206-4214.
33. Mitchell, M.D.; Elrick, M.M.; Walgren, J.L.; Muller, R.A.; Morris, D.L.; Thomson, D.C. Peptide based in vitro assay for detection reactive metabolites. Chem. Res.Toxicol., 2008, 21, 859-868.
34. Joosten, H.F.; van Acker, F.A.; van den Dobbelsteen, D.J.; Horbach, G.J.; Krajnc, E.I. Genotoxicity of hormonal steroids. Toxicol. Lett., 2004, 151(1), 113-34
35. Rossi, D.; Aiello, V.; Mazzoni, L.; Sensi, A.; Calzolari, E. In vitro short-term test evaluation of catecholestrogens genotoxicity. J. Steroid Biochem. Mol. Biol., 2007, 105(1-5), 98-105
36. Häkkinen, M.R.; Laine, J.; Juvonen, R.O.; Häyrynen, J.; Auriola, S.; Pasanen, M. 2'-Deoxyguanosine as a surrogate trapping agent for DNA reactive drug metabolites. Toxicol. Lett., 2011, 207, 34-41.
37. Juschyshyn, M.I.; Kent, U.M.; Hollenberg, P.F. The mechanismbased inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metab. Dispos., 2003, 31, 46-52.
38. Bateman, K.P.; Baker, J.; Wilke, M.; Lee, J.; LeRiche, T.; Seto, C.; Day, S.; Chauretm, N.; Ouellet, M.; Nicoll-Griffith, D.A. Detection of Covalent Adducts to Cytochrome P450 3A4 Using Liquid Chromatography Mass Spectrometry. Chem. Res. Toxicol., 2004, 17, 1356-1361.
39. Baer, B.R.; Wienkers, L.C.; Rock, D.A. Time-Dependent Inactivation of P450 3A4 by Raloxifene: Identification of Cys239 as the Site of Apoprotein Alkylation. Chem. Res. Toxicol., 2007, 20, 954-964.
40. Yukinaga, H.; Takami, T.; Shioyama, S.; Tozuka, Z.; Masumoto, H.; Okazaki, O.; Sudo, K. Identification of Cytochrome P450 3A4 Modification Site with Reactive Metabolite Using Linear Ion Trap-Fourier Transform Mass Spectrometry. Chem. Res. Toxicol., 2007, 20(10), 1373-1378.
41. Takakusa, H.; Masumoto, H.; Mitsuru, A.; Okazaki, O.; Sudo, K. Markers of electrophilic stress caused by chemically reactive metabolites in human hepatocytes. Drug Metab. Dispos., 2008, 36, 816-23.
42. Reese, M.; Sakatis, M.; Ambroso, J.; Harrell, A.; Yang, E.; Chen, L.; Taylor, M.; Baines, I.; Zhu, L.; Ayrton, A.; Clarke, S.E. An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. Chem.-Biol. Interact., 2011, 192, 60-64.
43. Baird, L.; Dinkova-Kostova, A.T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch.Toxicol., 2011, 85, 241-272.
44. Copple, I.M.; Goldring, C.E.; Jenkins, R.E.; Chia, A.J.; Randle, L.E.; Hayes, J.D.; Kitteringham, N.R.; Park. B.K. The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology, 2008, 48,1292-1301.
45. Shan, Y.; Lambrecht, R.W.; Donohue, S.E.; Bonkovsky, H.L. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J., 2006, 20, 2258-2267.
46. Thompson, R.A.; Isin, E.M.; Li, Y.; Weidolf, L.; Page, K.; Wilson, I.; Swallow, S.; Middleton, B.; Stahl, S.; Foster, A.J.; Dolgos, H.; Weaver, R.; Kenna, J.G. In vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. Chem. Res. Toxicol., 2012, 25, 1616-1632
47. Sakatis, M.Z.; Reese, M.J.; Harrell, A.W.; Taylor, M.A.; Baines, I.A.; Chen, L.; Bloomer, J.C.; Yang, E.Y.; Ellens, H.M.; Ambroso, J.L.; Lovatt, C.A.; Ayrton, A.D.; Clarke, S.E. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chem. Res. Toxicol., 2012, 25(10), 2067-2082
48. Edling, Y.; Sivertsson, L.;, Andersson, T.B.; Porsmyr-Palmertz, M.; Ingelman-Sundberg, M. Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. Toxicol. In vitro, 2008, 22(6), 1588-1594
49. Singer, J.B.; Lewitzky, S.; Leroy, E.; Yang, F.; Zhao, X.; Klickstein, L.; Wright, T.M.; Meyer, J.; Paulding, C.A. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet., 2010, 42(8), 711-714
50. Chang, C.C.; Too, C.L.; Murad, S.; Hussein, S.H. Association of HLA-B 1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int. J. Dermatol., 2011, 50(2), 221-224